BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goyal O, Sidhu SS, Kishore H. Minimal hepatic encephalopathy in cirrhosis- how long to treat? Ann Hepatol. 2017;16:115-122. [PMID: 28051800 DOI: 10.5604/16652681.1226822] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Coronel-castillo C, Contreras-carmona J, Frati-munari A, Uribe M, Méndez-sánchez N. Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy. Revista de Gastroenterología de México (English Edition) 2020;85:56-68. [DOI: 10.1016/j.rgmxen.2019.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Xu XY, Ding HG, Li WG, Jia JD, Wei L, Duan ZP, Liu YL, Ling-Hu EQ, Zhuang H, Hepatology CSO, Association CM. Chinese guidelines on management of hepatic encephalopathy in cirrhosis. World J Gastroenterol 2019; 25(36): 5403-5422 [PMID: 31576089 DOI: 10.3748/wjg.v25.i36.5403] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
3 Jeong JY, Jun DW, Bai D, Kim JY, Sohn JH, Ahn SB, Kim SG, Kim TY, Kim HS, Jeong SW, Cho YK, Song DS, Kim HY, Jung YK, Yoon EL. Validation of a Paper and Pencil Test Battery for the Diagnosis of Minimal Hepatic Encephalopathy in Korea. J Korean Med Sci. 2017;32:1484-1490. [PMID: 28776344 DOI: 10.3346/jkms.2017.32.9.1484] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
4 Zucker DM, Redulla R. Lactulose Management of Minimal Hepatic Encephalopathy: A Systematic Review. Gastroenterology Nursing 2019;42:84-94. [DOI: 10.1097/sga.0000000000000429] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
5 Hanai T, Shiraki M, Watanabe S, Imai K, Suetsugu A, Takai K, Moriwaki H, Shimizu M. Prognostic significance of minimal hepatic encephalopathy in patients with liver cirrhosis in Japan: A propensity score-matching analysis. J Gastroenterol Hepatol 2019;34:1809-16. [PMID: 30779213 DOI: 10.1111/jgh.14635] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
6 Khodadoostan M, Sadeghian S, Safaei A, Kabiri M, Shavakhi S, Shavakhi AR, Shavakhi A. Detection of Minimal Hepatic Encephalopathy in Iranian Patients with Cirrhosis. Middle East J Dig Dis 2018;10:230-5. [PMID: 31049170 DOI: 10.15171/mejdd.2018.115] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Gómez-hurtado I, Gimenez P, García I, Zapater P, Francés R, González-navajas JM, Manichanh C, Ramos JM, Bellot P, Guarner F, Such J. Norfloxacin is more effective than Rifaximin in avoiding bacterial translocation in an animal model of cirrhosis. Liver Int 2018;38:295-302. [DOI: 10.1111/liv.13551] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
8 Zeng X, Sheng X, Wang PQ, Xin HG, Guo YB, Lin Y, Zhong JW, He CZ, Yin J, Liu TT, Ma WJ, Xiao X, Shi PM, Yuan ZL, Yang L, Ma X, Xu JM, Shen XZ, Yang CQ, Zhu X, Lv NH, Xie WF. Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis. Hepatol Int 2021;15:155-65. [PMID: 33385299 DOI: 10.1007/s12072-020-10117-y] [Reference Citation Analysis]
9 Hudson M, Schuchmann M. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. Eur J Gastroenterol Hepatol. 2019;31:434-450. [PMID: 30444745 DOI: 10.1097/meg.0000000000001311] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 7.3] [Reference Citation Analysis]
10 Moran S, López-Sánchez M, Milke-García MDP, Rodríguez-Leal G. Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis. World J Gastroenterol 2021; 27(22): 3050-3063 [PMID: 34168407 DOI: 10.3748/wjg.v27.i22.3050] [Reference Citation Analysis]
11 Tateyama M, Naoe H, Tanaka M, Tanaka K, Narahara S, Tokunaga T, Kawasaki T, Yoshimaru Y, Nagaoka K, Watanabe T, Setoyama H, Sasaki Y, Tanaka Y. Loss of skeletal muscle mass affects the incidence of minimal hepatic encephalopathy: a case control study. BMC Gastroenterol 2020;20:371. [PMID: 33167879 DOI: 10.1186/s12876-020-01501-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Nishikawa H, Enomoto H, Nishiguchi S, Iijima H. Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis. Int J Mol Sci. 2020;21:5254. [PMID: 32722100 DOI: 10.3390/ijms21155254] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]